Mark Cuban has a blunt message for the millions of Americans who own stakes in giant health insurers, even if they don’t realize it. Change your holdings or accept responsibility for runaway medical bills.
The billionaire entrepreneur and founder of Cost Plus Drugs took to X on August 10, 2026, with a direct challenge. Investors who hold funds owning the biggest carriers are “part of the cost of healthcare problem in this country,” he wrote. Those companies, he added, “put the share price over the health of you, your family, co-workers and friends. The worst part is they will lie and mislead you to make more.”
Short. Direct. And aimed squarely at the 61 percent of Americans who own stocks directly or indirectly. Cuban’s post, first reported by Yahoo Finance, calls on fund managers and individual shareholders alike to pressure carriers such as UnitedHealth Group, Elevance Health, CVS Health, Cigna, Humana and Centene. Divest unless they shift priorities. The carriers did not respond immediately to requests for comment.
His timing lands amid fresh scrutiny of vertical integration. Insurers now control pharmacies, pharmacy benefit managers, physician groups and data pipelines. The arrangement, critics say, lets them capture profits at every layer while patients pay more. Sen. Elizabeth Warren highlighted the issue days earlier, noting a single company can own a patient’s doctor, pharmacy, insurance plan and the intermediary between them. She backs the bipartisan Patients Before Monopolies Act with Sen. Josh Hawley, which would force divestitures within a year.
Cuban’s track record gives his words weight.
He launched Cost Plus Drugs in 2022 to sell generics at manufacturer cost plus 15 percent markup and a flat $3 dispensing fee. The model bypasses traditional pharmacy benefit managers entirely. Prices appear online for anyone to see. No rebates. No hidden spreads. Results followed quickly. An imatinib cancer drug that once cost thousands at retail pharmacies dropped to $47 at Cost Plus, according to industry analyses. Hundreds of thousands of prescriptions now ship monthly. The company has expanded into lab testing and works with self-insured employers to route prescriptions away from legacy middlemen.
Yet Cuban never viewed his pharmacy as the final answer. He has spent years pressing for structural fixes. In April 2026 he told lawmakers at a Politico summit to stop being “wimps” and break up the largest healthcare conglomerates. Vertical integration creates misaligned incentives, he argued. PBMs wield outsized power over drug formularies, often stronger than any president, and prioritize their parent companies’ profits. “Don’t be a wimp. Seriously,” he said, per Fierce Healthcare.
His list of targeted changes, shared in a lengthy August 2026 X thread, reads like a policy blueprint. Make all government healthcare contracts public, including prices. Ban providers with repeated regulatory fines from federal or state business. Force nonprofit hospitals to disclose general ledgers, vendor payments and actual net revenue by insurance plan. End anti-kickback safe harbors so manufacturer sales become true net prices. Eliminate prior authorizations and denials inside insurer networks. Standardize PBM and administrative services contracts. Remove restrictive provider networks and chargemaster pricing. Let government negotiate prices for implants and medical devices. Guarantee coverage at Medicare rates or below for non-Medicare patients, with repayment on a sliding scale capped at 10 percent of take-home pay.
But. The thread also reveals frustration. Cuban knows Congress moves slowly. Bipartisan bills gather dust. Public attention fades. So he turns to investors. They hold the shares. They can vote. They can divest. They can demand lower costs instead of higher quarterly earnings.
Recent coverage shows his message resonates. A MoneyLion analysis published just days before his investor call outlined five practical steps Cuban advocates: transparent price lists that let employers and Medicare compare offers, simplified employee plans without deductibles or denials, upfront Medicare-rate payments to providers to slash administrative burden, expanded access to branded drugs at steep discounts, and mail-order plus retail partnerships to reach rural patients. Each builds on the Cost Plus approach. Each attacks opacity.
Opposition remains fierce. The largest insurers and PBMs defend their scale as necessary for negotiating lower prices and managing complex benefits. They point to rebates returned to plan sponsors and technology investments that streamline claims. Yet data tell another story. Employer health benefit costs are projected to rise 6.7 percent in 2026, pushing average family coverage above $18,500, according to earlier reports. Hospital systems complain of thin margins at Medicare rates while insurers report record profits. Cuban’s retort is simple. Even if every hospital service cost one dollar, carriers would still mark it up to protect margins.
And that gets to the heart of his argument. The current system rewards complexity and opacity. Patients rarely see true prices. Employers struggle to benchmark costs. Investors chasing dividends rarely connect their 401(k) returns to a colleague’s surprise medical bill. Cuban wants to force the connection.
His Cost Plus model has already shown what transparency can achieve. By publishing every price, the company invited direct comparison. Employers switched portions of their pharmacy spend and reported 50 to 90 percent savings on generics in some cases. The approach gained further traction when Cost Plus agreed to share its pricing API with President Trump’s TrumpRx transparency tool. Patients and plan sponsors gained another data point.
Still, Cuban insists systemic change requires more than one successful startup. It needs pressure from multiple directions. Antitrust action. Contract transparency. Shareholder activism. Public scrutiny of nonprofit hospital finances. Removal of incentives that let middlemen profit from higher list prices.
Recent X discussions reflect growing awareness. Users noted Cuban’s alignment with efforts to publish Department of Defense contracts with Express Scripts. Others highlighted bipartisan interest in curbing PBM power. One post captured the moment: Cuban telling investors they can actually make a difference if they stop treating healthcare stocks as just another holding.
The stakes are high. Healthcare spending consumes nearly 20 percent of U.S. gross domestic product. Families delay care. Employers cut wages to offset premium increases. Government budgets strain under Medicare and Medicaid obligations. Cuban’s point is that ordinary investors, through their retirement accounts and index funds, sit on the leverage needed to demand better.
Whether fund managers listen remains uncertain. Divestment from major insurers would require rethinking benchmarks and risk models. Many funds hold these stocks precisely because of their size, cash flow and political influence. Yet Cuban’s own success with Cost Plus proves markets can reward alternative models. Direct contracting. Price visibility. Fixed margins. Lower administrative overhead.
He has spent four years proving one part of the thesis. Now he asks investors to prove the other. Own the problem. Or help fix it. The choice, he says, belongs to shareholders who have quietly funded the status quo for years.
Change will not arrive overnight. Legislation faces hurdles. Industry lobbying remains formidable. Public anger can dissipate. But Cuban’s latest campaign adds a new constituency to the reform debate: the very investors whose capital keeps the current system afloat. If enough of them act on his warning, the pressure could finally shift from patients to the boardrooms that set prices.